Unknown

Dataset Information

0

Resuscitation Outcomes Consortium-Amiodarone, Lidocaine or Placebo Study (ROC-ALPS): Rationale and methodology behind an out-of-hospital cardiac arrest antiarrhythmic drug trial.


ABSTRACT: Despite their wide use, whether antiarrhythmic drugs improve survival after out-of-hospital cardiac arrest (OHCA) is not known. The ROC-ALPS is evaluating the effectiveness of these drugs for OHCA due to shock-refractory ventricular fibrillation or pulseless ventricular tachycardia (VF/VT).ALPS will randomize 3,000 adults across North America with nontraumatic OHCA, persistent or recurring VF/VT after ?1 shock, and established vascular access to receive up to 450 mg amiodarone, 180 mg lidocaine, or placebo in the field using a double-blind protocol, along with standard resuscitation measures. The designated target population is all eligible randomized recipients of any dose of ALPS drug whose initial OHCA rhythm was VF/VT. A safety analysis includes all randomized patients regardless of their eligibility, initial arrhythmia, or actual receipt of ALPS drug. The primary outcome of ALPS is survival to hospital discharge; a secondary outcome is functional survival at discharge assessed as a modified Rankin Scale score ?3.The principal aim of ALPS is to determine if survival is improved by amiodarone compared with placebo; secondary aim is to determine if survival is improved by lidocaine vs placebo and/or by amiodarone vs lidocaine. Prioritizing comparisons in this manner acknowledges where differences in outcome are most expected based on existing knowledge. Each aim also represents a clinically relevant comparison between treatments that is worth investigating.Results from ALPS will provide important information about the choice and value of antiarrhythmic therapies for VF/VT arrest with direct implications for resuscitation guidelines and clinical practice.

SUBMITTER: Kudenchuk PJ 

PROVIDER: S-EPMC4014351 | biostudies-literature | 2014 May

REPOSITORIES: biostudies-literature

altmetric image

Publications

Resuscitation Outcomes Consortium-Amiodarone, Lidocaine or Placebo Study (ROC-ALPS): Rationale and methodology behind an out-of-hospital cardiac arrest antiarrhythmic drug trial.

Kudenchuk Peter J PJ   Brown Siobhan P SP   Daya Mohamud M   Morrison Laurie J LJ   Grunau Brian E BE   Rea Tom T   Aufderheide Tom T   Powell Judy J   Leroux Brian B   Vaillancourt Christian C   Larsen Jonathan J   Wittwer Lynn L   Colella M Riccardo MR   Stephens Shannon W SW   Gamber Mark M   Egan Debra D   Dorian Paul P  

American heart journal 20140301 5


<h4>Background</h4>Despite their wide use, whether antiarrhythmic drugs improve survival after out-of-hospital cardiac arrest (OHCA) is not known. The ROC-ALPS is evaluating the effectiveness of these drugs for OHCA due to shock-refractory ventricular fibrillation or pulseless ventricular tachycardia (VF/VT).<h4>Methods</h4>ALPS will randomize 3,000 adults across North America with nontraumatic OHCA, persistent or recurring VF/VT after ≥1 shock, and established vascular access to receive up to 4  ...[more]

Similar Datasets

| S-EPMC6825817 | biostudies-literature
| S-EPMC5705566 | biostudies-literature
| S-EPMC2614111 | biostudies-literature
| S-EPMC3797446 | biostudies-literature
| S-EPMC4433591 | biostudies-literature
| S-EPMC4159466 | biostudies-literature
| S-EPMC10416093 | biostudies-literature
| S-EPMC1573972 | biostudies-other
| S-EPMC4792760 | biostudies-literature
| S-EPMC7009320 | biostudies-literature